PA, NJ, DE-Israel Life Sciences Conference

PA, NJ, DE-Israel Life Sciences Conference Israeli Company Survey We look forward to your participation in the in the PA, NJ, DE-Israel Life Sciences Conference. To help ensure that the program meets your needs and is attended by appropriate representatives from the life sciences industry, funding organizations and other strategic partners from our region that are well-matched to your business, AICC is seeking your input. Please respond to this questionnaire and return it to the Israel Export Institute at (add contact information) no later than Aug 14th, 2008.

1. Key Contact’s Information a. Company Name: VacciGuard b. Company Technology: Device, Biotechnology, Pharmaceuticals, Healthcare IT c. Company Site: www.misgav-venture.com/companies-in.asp?num=21 d. Delegate’s Name: Anat Eitan e. Delegate’s Title: CEO f. Delegate’s Phone: 972-9-8998933

2. Company description and background and current financials - including investments. (50 word limit) VacciGuard was established in February 2007 and operates in Israel within the framework of the Misgav Venture Accelerator. Based on its novel technology, VacciGuard is developing effective vaccines against many violent pathogens for which there is no effective vaccine solution today and against devastating diseases such as cancer. A proof of concept was obtained in mouse models with 5 pathogens including Salmonella typhi, Streptococcus pneumoniae, Neisseria meningitis type B, West Nile Virus (WNV) and Murine Cytomegalovirus (MCMV).

The company's technology was developed by Professor Irun Cohen of the Department of Immunology at the Weizmann Institute of Science and his collaborators from the Ben-Gurion University. The inventors discovered that poor immunogenic antigens (carbohydrates, peptides) conjugated to HSP-60-derived peptides become remarkably effective vaccines. HSP-60 is a powerful signal to the immune system because it is a chaperone/stress protein, conserved throughout evolution, and up-regulated at sites of inflammation, infections, and other kind of stress. Thus, HSP-60 peptides conjugates convert a weak antigen into a strong immunogen.

3. Product description including, target market, stage of development and major accomplishments to date (50 word limit) 3.1 Project Name: VG-LC Target market: Lung Cancer Market: $3.2 billions Stage of development: Proof of concept in animal models Major accomplishment: generation of Long lasting IgG antibodies against the target antigen. 3.2 Project Name: VG-WNV Target market: US and Europe suseptible population for WNV (the elderly population. 50 years and more. Market: ~$400M Stage of development: Proof of concept in animal models Major accomplishment: full protection from 3 WNV strains following challenge of vaccinated mice. 3.3 Project Name: VG-flue CE., a universal influenza vaccine. Target market: World-wide population Market: $1.1 billion Stage of development: Proof of concept in animal models is on-going Major accomplishment: identification of exposed potential common epitops.

4. Are you seeking an investment? Y/ N a. Amount $ 3M b. Timeframe: This will support the company activity for about 2 years c. Purpose: Completing phase I/II with one indication and progressing additional 2 projects very close to the clinical phase d. Preferred Source: Private investors

5. Listed below is a sampling of the key Life-Science constituents in our area. Based on your research, please identify all the organizations (whether or not listed) that you believe are appropriate prospects for a strategic partnership with your company. a. For each company, please tell us what division or department within the company is best suited to a collaboration with your company b. For each department, please identify the title of the most appropriate contact for your meeting (examples-Director of R&D, Global Business Development, Medical Specialist, Licensing Officer) Arrow International: Impax Laboratories Inc.: AstraZeneca Pharmaceuticals LP: Cancer Johnson& Johnson director of R&D and business development Centocor Biologics: Cancer director director of R&D and business development director Baxter Healthcare Corp: Vaccine director Ethicon LLC: of R&D and business development director Janssen Pharmaceutical Inc: Cancer Bristol-Myers Squibb Co.: Cancer director of R&D and business development director of R&D and business development director director McNEIL-PPC Inc.: Cephalon Inc.: Cancer director of R&D Ortho BioTech Inc.: and business development director Ortho Clinical Diagnostics: Covatec: Lannett Co. Inc.: Cancer director of R&D ENDO Pharmaceuticals: and business development director Genzyme Corp.: Cancer director of R&D Laron Pharmaceuticals Inc.: and business development director Mennen Medical Corp.: GlaxoSmith-Kline: Therapeutic Vaccine Merck & Co Inc.: Cancer director of director of R&D or/and business R&D and business development director development director and also pathogenic and also pathogenic vaccines director of vaccines director of R&D and business R&D and business development director development director Kensey Nash Corp.: Novartis Pharmaceuticals Corp.: Cancer Quest Diagnostics: director of R&D and business development Roche director and also pathogenic vaccines Pharmaceuticals: Therapeutic vaccine director of R&D and business development (Cancer)director of R&D and business director development director and also pathogenic Pfizer Inc.: Therapeutic vaccine vaccines director of R&D and business (Cancer)director of R&D and business development director development director and also pathogenic Diagnostics: vaccines director of R&D and business development director Sanofi Aventis: Vaccines director of West Pharmaceutical Services: R&D and business development director Wyeth Pharmaceuticals: Cancer director Shire US Inc.: of R&D and business development director Siemens Medical Solutions: and also pathogenic vaccines director of ViroPharma Inc.: Vaccine director of R&D and business development director R&D and business development director Zlb Behring LLC:

6. From the list below, please provide all additional areas for potential collaboration and resource development for your company. a. Physicians/Health care practitioners b. Reimbursement c. Regulatory Issues d. Clinical Trials e. Healthcare Administrators f. Distribution g. Technology transfer h. Academia i. Incubators/Science Parks j. Licensing k. Medical Advisory l. Financial Advisory m. Clinical Development n. Intellectual Property o. Staffing p. Others (please list) Investors